iRadimed Corporation (NASDAQ:IRMD) Receives $87.33 Average Price Target from Analysts

iRadimed Corporation (NASDAQ:IRMD) has received an average rating of “Moderate Buy” from the five analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $87.3333.

IRMD has been the subject of a number of research analyst reports. Lake Street Capital reissued a “buy” rating and set a $100.00 target price on shares of iRadimed in a report on Monday, November 3rd. Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a research note on Monday. Roth Capital set a $90.00 target price on shares of iRadimed in a research note on Friday, October 31st. Wall Street Zen lowered shares of iRadimed from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 26th. Finally, Zacks Research raised shares of iRadimed to a “hold” rating in a research note on Tuesday, November 4th.

iRadimed Stock Performance

iRadimed stock opened at $97.77 on Friday. The stock has a market capitalization of $1.24 billion, a P/E ratio of 59.25 and a beta of 1.06. The company’s fifty day moving average price is $89.63 and its 200 day moving average price is $74.89. iRadimed has a 1 year low of $47.48 and a 1 year high of $98.53.

iRadimed (NASDAQ:IRMD) last posted its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.04. The business had revenue of $21.20 million for the quarter, compared to the consensus estimate of $20.50 million. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. Sell-side analysts predict that iRadimed will post 1.66 EPS for the current year.

iRadimed Dividend Announcement

The business also recently announced a special dividend, which was paid on Tuesday, December 30th. Stockholders of record on Wednesday, December 17th were issued a dividend of $0.50 per share. The ex-dividend date was Wednesday, December 17th. iRadimed’s payout ratio is currently 41.21%.

Insider Buying and Selling

In related news, CFO John Glenn sold 15,000 shares of the stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $97.29, for a total value of $1,459,350.00. Following the completion of the sale, the chief financial officer owned 7,362 shares of the company’s stock, valued at approximately $716,248.98. This trade represents a 67.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Roger E. Susi sold 5,000 shares of iRadimed stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $97.66, for a total value of $488,300.00. Following the transaction, the chief executive officer owned 2,282,500 shares in the company, valued at approximately $222,908,950. The trade was a 0.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 65,000 shares of company stock valued at $5,685,500 over the last 90 days. Company insiders own 36.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of iRadimed by 3.3% during the 1st quarter. Vanguard Group Inc. now owns 554,451 shares of the medical equipment provider’s stock worth $29,098,000 after purchasing an additional 17,640 shares during the period. Nuveen LLC acquired a new position in iRadimed in the first quarter valued at about $1,418,000. American Century Companies Inc. boosted its stake in iRadimed by 13.8% during the first quarter. American Century Companies Inc. now owns 18,284 shares of the medical equipment provider’s stock worth $960,000 after buying an additional 2,213 shares during the period. Voya Investment Management LLC increased its position in shares of iRadimed by 38.2% during the first quarter. Voya Investment Management LLC now owns 11,711 shares of the medical equipment provider’s stock valued at $615,000 after acquiring an additional 3,239 shares during the last quarter. Finally, Ranger Investment Management L.P. raised its stake in shares of iRadimed by 7.4% in the 2nd quarter. Ranger Investment Management L.P. now owns 214,840 shares of the medical equipment provider’s stock valued at $12,845,000 after acquiring an additional 14,730 shares during the period. Institutional investors and hedge funds own 92.34% of the company’s stock.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.